ReviewDrugs2011
Cabazitaxel: a novel microtubule inhibitor.
Review in Drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 57 citations in OpenAlex.
- No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.Medical oncology (Northwood, London, England) · 2017Trial
- Engineered membrane-coated nanoparticles enhance ferroptosis and microtubule inhibition in prostate cancer.Journal of materials science. Materials in medicine · 2026Article
- A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for cabazitaxel.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Identification of osteoarthritis-related genes and potential drugs based on single cell RNA-seq data.Molecular medicine (Cambridge, Mass.) · 2025Article
- Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.Journal of hematology & oncology · 2022Review
- The effects and mechanism of taxanes on chemotherapy-associated ovarian damage: A review of current evidence.Frontiers in endocrinology · 2022Review
- Cabazitaxel suppresses the proliferation and promotes the apoptosis and radiosensitivity of castration-resistant prostate cancer cells by inhibiting PI3K/AKT pathway.American journal of translational research · 2022Article
- Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway.FEBS open bio · 2021Article
- Quantitative self-assembly of pure drug cocktails as injectable nanomedicines for synergistic drug delivery and cancer therapy.Theranostics · 2021Article
- Inhibiting the NF-κB pathway enhances the antitumor effect of cabazitaxel by downregulating Bcl-2 in pancreatic cancer.International journal of oncology · 2020Article
- Therapeutic Effect of Cabazitaxel and Blood-Brain Barrier opening in a Patient-Derived Glioblastoma Model.Nanotheranostics · 2019Article
- Cabazitaxel operates anti-metastatic and cytotoxic via apoptosis induction and stalls brain tumor angiogenesis.Oncotarget · 2016Article
- Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2016Review
- Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- Efficacy of cabazitaxel in mouse models of pediatric brain tumors.Neuro-oncology · 2015Article
- Cabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancer.Drugs & aging · 2013Review
- Cabazitaxel-induced stabilization of microtubules enhances radiosensitivity in ovarian cancer cells.Frontiers in oncology · 2013Article
- Acute myocardial infarction and subacute stent thrombosis associated with cabazitaxel: a case report.International journal of clinical pharmacy · 2012Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of drug resistance is a major obstacle to effective cancer therapy. Several agents are in clinical development with the goal of overcoming resistance. Among them is cabazitaxel, a semisynthetic taxoid that is able to overcome a common mechanism of resistance that limits the efficacy of other chemotherapeutic agents, including the older taxanes. The promise of cabazitaxel as a second-line chemotherapy option for advanced prostate cancer has been confirmed clinically in the phase III TROPIC (Treatment of Hormone-Refractory Metastatic Prostate Cancer Previously Treated with a Taxotere-Containing Regimen) trial. This trial showed that cabazitaxel is the first chemotherapeutic agent to demonstrate a survival benefit in metastatic castration-resistant prostate cancer (mCRPC) since the approval of docetaxel. On this basis, the US FDA and the European Medicines Agency approved cabazitaxel in June 2010 and January 2011, respectively, for the treatment of patients with mCRPC who have previously been treated with docetaxel. The most prevalent toxicity was neutropenia and the use of primary prophylaxis with granulocyte-colony stimulating factor is recommended in high risk patients. This article presents the preliminary antitumour activity, safety, tolerability and pharmacokinetic data of cabazitaxel, and an overview of the current status of clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.